Download full-text PDF

Source
http://dx.doi.org/10.1016/s0035-2845(72)80005-2DOI Listing

Publication Analysis

Top Keywords

[lymphoblastic transformation
4
transformation test
4
test applied
4
applied diagnosis
4
diagnosis drug
4
drug bacterial
4
bacterial hypersensitivity
4
hypersensitivity isotope
4
isotope morphologic
4
morphologic interpretation]
4

Similar Publications

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological disease originating from the malignant transformation of T-cell progenitors, caused by the accumulation of genetic aberrations. One-fifth of T-ALL patients are characterized by ectopic expression of the homeobox transcription factor TLX3. However, the role of TLX3 in T-ALL remains elusive, partly due to the lack of suitable study models.

View Article and Find Full Text PDF

Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.

Haematologica

January 2025

Division of Oncology, the Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

While outcomes for pediatric acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) have improved dramatically in recent decades, relapsed and refractory disease remain a significant therapeutic challenge. This is particularly true for patients with T-cell ALL and LBL, where survival for patients with relapsed/refractory disease remains dismal. Recent efforts to comprehensively profile the genomics of T-ALL/LBL to improve understanding of disease biology have enhanced our ability to identify high-risk patients at diagnosis who are more likely to relapse and have also identified novel targets for precision medicines.

View Article and Find Full Text PDF

The homeodomain protein homeobox (HOPX), a multifaceted regulator of cellular functions and developmental processes, is predominantly expressed in stem cells across diverse tissues; it has also emerged as a tumour suppressor in various solid cancers. However, its role in haematological malignancies still remains undefined. This study aimed to elucidate its significance in T-cell acute lymphoblastic leukaemia (T-ALL).

View Article and Find Full Text PDF

Folic Acid-Decorated Chitosan-PLGA Nanobiopolymers for Targeted Drug Delivery to Acute Lymphoblastic Leukemia Cells: Studies.

Technol Cancer Res Treat

December 2024

Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran.

Objectives: This study developed a drug delivery system (DDS) using folic acid (FA)-functionalized chitosan (CS) and poly (lactic-co-glycolic acid) (PLGA) nanocarriers for targeted sodium butyrate (NB) delivery to leukemia cells (NALM6). The goal was to enhance NB's therapeutic efficacy while reducing its cytotoxicity to non-malignant cells.

Methods: FA-CS-PLGA nanocarriers were synthesized and characterized using Fourier-transform infrared spectroscopy (FT-IR), dynamic light scattering (DLS), zeta potential analysis, transmission electron microscopy (TEM), and thermogravimetric analysis (TGA).

View Article and Find Full Text PDF

Ph+ ALL: new approaches for upfront therapy.

Hematology Am Soc Hematol Educ Program

December 2024

Adult Leukemia Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Article Synopsis
  • Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) mainly impacts adults and is known for poor treatment outcomes due to its resistance to traditional chemotherapy.
  • The introduction of Imatinib, a tyrosine kinase inhibitor, has significantly improved the prognosis for Ph+ ALL patients by enhancing their chances of achieving remission and qualifying for stem cell transplantation.
  • Recent advancements in understanding Ph+ ALL have led to the development of more effective treatments, such as additional TKIs, immunotherapy, and improved monitoring methods, paving the way for better management of the disease.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!